Publication
Cell-penetrating peptides: a tool for effective delivery in gene-targeted therapies
| dc.contributor.author | Figueiredo, Inês Rego de | |
| dc.contributor.author | Freire, João Miguel | |
| dc.contributor.author | Flores, Luís | |
| dc.contributor.author | Veiga, Ana Salomé | |
| dc.contributor.author | Castanho, Miguel A. R. B. | |
| dc.date.accessioned | 2016-04-05T15:52:28Z | |
| dc.date.available | 2016-04-05T15:52:28Z | |
| dc.date.issued | 2014 | |
| dc.description | © 2014 International Union of Biochemistry and Molecular Biology | pt_PT |
| dc.description.abstract | The current landscapes of novel therapeutic approaches rely mostly on gene-targeted technologies, enabling to fight rare genomic diseases, from infections to cancer and hereditary diseases. Although, reaching the action-site for this novel treatments requires to deliver nucleic acids, or other macromolecules into cells, which may pose difficult tasks to pharmaceutical companies. To overcome this technological limitation, a wide variety of vectors have been developed in the past decades and have proven to be successful in delivering various therapeutics. Cell-penetrating peptides (CPP) have been one of the technologies widely studied and have been increasingly used to transport small RNA/DNA, plasmids, antibodies, and nanoparticles into cells. Despite the already proved huge potential that these peptide-based approaches may suggest, few advances have been put to pharmacological or clinical use. This review will describe the origin, development, and usage of CPP to deliver therapeutic agents into cells, with special emphasis on their current application to gene-therapies. Specifically, we will describe the current trials being conducted to treat cancer, gene disorders, and autoimmune diseases using CPP-based therapies. | pt_PT |
| dc.description.sponsorship | The authors thank Fundação para a Ciência e Tecnologia–Ministério da Educação e Ciência (FCT-MEC, Portugal) [PTDC/QUIBIQ/112929/2009] and Gabinete de Apoio à Investigação Científica, Tecnológica e Inovação (GAPIC–20130028/PEC/BG, 20120006, and 20110007). JMF acknowledges FCT-MEC for fellowship SFRH/BD/70423/2010 | pt_PT |
| dc.identifier.citation | 2014 International Union of Biochemistry and Molecular Biology, Volume 66, Number 3, March 2014, Pages 182–194 | pt_PT |
| dc.identifier.doi | DOI 10.1002/iub.1257 | pt_PT |
| dc.identifier.issn | 1521-6543 | |
| dc.identifier.uri | http://hdl.handle.net/10451/23253 | |
| dc.language.iso | eng | pt_PT |
| dc.peerreviewed | yes | pt_PT |
| dc.publisher | Wiley | pt_PT |
| dc.relation.publisherversion | http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1521-6551/ | pt_PT |
| dc.subject | Cell-penetrating peptide | pt_PT |
| dc.subject | Gene therapy | pt_PT |
| dc.subject | Cancer treatment | pt_PT |
| dc.subject | Drug delivery | pt_PT |
| dc.title | Cell-penetrating peptides: a tool for effective delivery in gene-targeted therapies | pt_PT |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FQUI-BIQ%2F112929%2F2009/PT | |
| oaire.awardURI | info:eu-repo/grantAgreement/FCT/SFRH/SFRH/BD/70423/2010/PT | |
| oaire.citation.title | IUBMB Life | pt_PT |
| oaire.fundingStream | 3599-PPCDT | |
| oaire.fundingStream | SFRH | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.identifier | http://doi.org/10.13039/501100001871 | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| project.funder.name | Fundação para a Ciência e a Tecnologia | |
| rcaap.rights | closedAccess | pt_PT |
| rcaap.type | article | pt_PT |
| relation.isProjectOfPublication | 954cb0bb-03f8-45f6-a48d-27c88a2f8690 | |
| relation.isProjectOfPublication | 5ed17e15-93b0-4a17-971c-e222c3f43117 | |
| relation.isProjectOfPublication.latestForDiscovery | 5ed17e15-93b0-4a17-971c-e222c3f43117 |